Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Hodgkin's Lymphoma: early-phase trial registry
12 of 64 indexed Non-Hodgkin's Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #215 of 28,707 conditions by registered trial count.
64 US clinical trials · 12 currently recruiting · #215 of 28,707 conditions by registered trial count
Non-Hodgkin's Lymphoma: 64 US clinical trials tracked, 12 recruiting.
Non-Hodgkin's Lymphoma is the subject of 64 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 54 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 6 of these trials.
Enrollment posture brief
Registry condition non-hodgkins-lymphoma
OPEN 12 | RECR 19% | LATE 5 | EARLY 54 | RANK #215 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Allergy (19% recruiting · 16 trials)
Non-Hodgkin's Lymphoma lists 12 open slots (19% of 64 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Hodgkin's Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Hodgkin's Lymphoma is recruiting below its size-band peers.
12 of 64 indexed trials (18.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Hodgkin's Lymphoma trials is spread across many organizations.
Baylor College of Medicine accounts for 6 of 64 trials (9.4%). 39 distinct sponsors appear on at least one study for this condition label.
-
Most Non-Hodgkin's Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 46 among the 64 trials that report a genuine target (sentinel values excluded). 45 of those (70.3%) plan for fewer than 100 participants.
-
Non-Hodgkin's Lymphoma research is mostly interventional.
59 interventional and 5 observational studies make up this index (92.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
64 total, page 2 of 2
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital
NCT02581007
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Weill Medical College of Cornell University
NCT00504972
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
University of New Mexi
NCT00276003
Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Acrotech Biopharma
NCT01851551
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
West Virginia University
NCT01203020
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Duke University
NCT00901225
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
GlaxoSmithKline
NCT00062894
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
AbbVie
NCT01969669
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
GPCR Therapeutics
NCT01458288
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma
NCT00818480
Use of Topotecan in Patients With Refractory Acute Leukemia
US Department of Veterans Affairs
NCT00100477
Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
Michael John Robertson
NCT01768338
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Pharmacyclics
NCT01149668
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 27 |
| Phase 2 | 27 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Hodgkin's Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Hodgkin's Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Hodgkin's Lymphoma page
64 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Non-Hodgkin's Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Baylor College of Medicine sponsors the most Non-Hodgkin's Lymphoma trials on record, review their full trial history before evaluating a specific study. See Baylor College of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Hodgkin's Lymphoma condition card totals 64 registered trials; most-linked intervention Rituximab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.